Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

RNA-seq of medulloblastoma spheroid models

ABSTRACT: Studying medulloblastoma, the most common malignant paediatric brain tumour, requires simple yet realistic in vitro models. In this study, we optimised a robust, reliable, three-dimensional (3D) culture method for medulloblastoma able to recapitulate the spatial conformation, cell-cell and cellmatrix interactions that exist in vivo and in patient tumours. We investigated the initial stages of metastatic dissemination using brain-specific hyaluronan hydrogel matrices. In order to perform NGS of SHH medulloblastoma metastasis models, it was essential to extract high quality RNA for library preparation and sequencing. However, RNA isolation from hydrogels proved particularly difficult due to the low yields of RNA obtained. To efficiently utilise our samples, we chose to adopt two NGS technologies: traditional mRNA sequencing, which required at least 100 ng of RNA per sample, and 3' UPX sequencing, a method used for low input samples that sequenced the 3' end of RNA near the poly-A tail. Firstly, RNA was extracted from samples using the NucleoSpin RNA Plus kit (Macherey-Nagel). Following extraction, samples were shipped to QIAGEN Genomic Services (Hilden, Germany) where the subsequent steps of NGS were performed. Quality control of the RNA was performed using the Qubit RNA high sensitivity assay (Invitrogen) which quantified the amount of RNA in each sample. Samples with 100 ng or more of RNA in total were suitable for mRNA NGS. Samples with lower RNA yields were lyophilised and resuspended in a smaller volume of RNase-free water. Another quality control step was performed to quantify the RNA. Samples with an RNA concentration above 1.4 ng/mL were appropriate for 3' UPX NGS. However, samples with a lower RNA concentration were unsuitable for either method of NGS. Following RNA extraction and quantification, libraries were prepared and sequenced. For mRNA NGS, library preparation was carried out using the TruSeq Stranded mRNA library preparation kit. All prepared libraries successfully passed QIAGEN’s internal quality control checks and were subsequently sequenced on a NextSeq 500 Illumina sequencer. Following sequencing, quality control of the sequencing data was performed using FastQC analysis. All samples had high quality scores, indicating good technical performance of the sequencing. For 3' UPX NGS, library preparation was performed using the QIAseq UPX 3' Transcriptome kit. All prepared libraries successfully passed QIAGEN’s internal quality control checks and were sequenced on a NextSeq 500 Illumina sequencer. Following sequencing, FastQC analysis of the sequencing data was performed and all samples were considered suitable for downstream primary and secondary data analysis.

INSTRUMENT(S): NextSeq 500

ORGANISM(S): Homo sapiens

SUBMITTER: Beth Coyle

PROVIDER: E-MTAB-10127 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Similar Datasets

Project description:The objective of the study was to understand gene expression patterns and pathways that relate to Endoscopic Remission and Histologic remission in IBD as defined by different endoscopic and histological disease activity scores. Colonic Endoscopic biopsies were collected in RNAlater from 21 UC patients undergoingcolonoscopies withthe endocytoscope CF- Y-0058-1 prototype Olympus, Japan). RNA was extracted using RNeasy columns (Qiagen) and quantified by Qubit (Life Technologies). 0.5ng RNA was used to prepare uniquely indexed cDNA QIAseq UPX 3’ Transcriptome libraries according to manufacturer’s instructions (Qiagen). Libraries were quantified and quality-controlled using the QIAseq Library Quant Assay Kit and tapestation analysis and sequenced on the Miseq and Nextseq Illumina platforms using the illumina sequencing primer and PhiX 15% to a depth of 1-3milion reads/sample. Read numbers were set as 101 bp (R1) x 51 bp (R2). Fastq files were obtained through BaseSpace and reads de-multiplexed, aligned to human genome GRCh38, quantified and normalised by the TPM method using the CLC Genomics Workbench (Qiagen). The following differential expression procedure was performed for participants classified as healed versus non-healed according different histologic and endoscpic scores which included the histological scores: Nancy and Robarts Histological Index (RHI) as well as the mayo endoscopic score (MES) and the endocytoscopy score system (ECSS). Normalised values were log-transformed with a pseudocount of 1 added. Transcripts with < 1 transformed count in any sample were excluded from further analysis, as were transcripts with low variance (defined as less than 10% unique counts across both conditions and greater than a 19:1 ratio of the most frequent count to the second most frequent across both conditions). Differential expression analysis between conditions was conducted with the limma package. Library size was estimated using reduced maximum likelihood estimator with 500 iterations. Initial fitting was performed using a robust M-estimation, and moderated test statistics computed by empirical Bayes. A FDR corrected p value <0.05 was considered and filtered for further downstream data analysis. Partial least squares discriminant analysis (PLS-DA) modelling was performed on these genes and a variable Importance in Projection (VIP) score of >1 was used to further filter the genes. To understand the biological significance and pathways, we also performed enrichment analysis using EnrichR involving three databases: Gene ontology, Wiki pathways and Kyoto Encyclopaedia of Genes and Genomes (KEGG).

Project description:The objective of the study was to understand gene expression patterns and pathways that relate to Endoscopic Remission and Histologic remission in IBD as defined by different endoscopic and histological disease activity scores. Colonic Endoscopic biopsies were collected in RNAlater from 9 Crohn's disease patients undergoing colonoscopies with the endocytoscope CF- Y-0058-1 prototype Olympus, Japan). RNA was extracted using RNeasy columns (Qiagen) and quantified by Qubit (Life Technologies). 0.5ng RNA was used to prepare uniquely indexed cDNA QIAseq UPX 3’ Transcriptome libraries according to manufacturer’s instructions (Qiagen). Libraries were quantified and quality-controlled using the QIAseq Library Quant Assay Kit and tapestation analysis and sequenced on the Miseq and Nextseq Illumina platforms using the illumina sequencing primer and PhiX 15% to a depth of 1-3milion reads/sample. Read numbers were set as 101 bp (R1) x 51 bp (R2). Fastq files were obtained through BaseSpace and reads de-multiplexed, aligned to human genome GRCh38, quantified and normalised by the TPM method using the CLC Genomics Workbench (Qiagen). The following differential expression procedure was performed for participants classified as healed versus non-healed according different histologic and endoscpic scores which included the histological scores: Nancy and Robarts Histological Index (RHI) as well as SES-CD, Modified Riley and and the endocytoscopy score system (ECSS). Normalised values were log-transformed with a pseudocount of 1 added. Transcripts with < 1 transformed count in any sample were excluded from further analysis, as were transcripts with low variance (defined as less than 10% unique counts across both conditions and greater than a 19:1 ratio of the most frequent count to the second most frequent across both conditions). Differential expression analysis between conditions was conducted with the limma package. Library size was estimated using reduced maximum likelihood estimator with 500 iterations. Initial fitting was performed using a robust M-estimation, and moderated test statistics computed by empirical Bayes. A FDR corrected p value <0.05 was considered and filtered for further downstream data analysis. Partial least squares discriminant analysis (PLS-DA) modelling was performed on these genes and a variable Importance in Projection (VIP) score of >1 was used to further filter the genes. To understand the biological significance and pathways, we also performed enrichment analysis using EnrichR involving three databases: Gene ontology, Wiki pathways and Kyoto Encyclopaedia of Genes and Genomes (KEGG).

Project description:Medulloblastoma is subdivided into different subgroups: WNt, SHH, Group 3 and Group 4. Since these subgroups are associated with different OS and metastasis rates it is crucial to understand them better. Six medulloblastoma cell lines, DAOY, ONS-76, D458, HD-MB03, CHLA-01-MED, CHLA-01R-MED, have been sequenced to compare them with medulloblastoma patient data. Methods: Medulloblastoma cell lines representating the different subgroups have been cultured and cell were harvested and RNA was isolated when 70% confluency was reached. In detail, DAOY and D458 were grown in DMEM (Thermo Fisher) with 10% FBS (HyClone, Thermo Fisher), ONS-76 and HD-MB03 were grown in RPMI 1640 (Sigma-Aldrich) with 10% FBS and CHLA-01-MED and CHLA-01R-MED were grown in DMEMF12 supplemented with B27, 20 ng/ml EGF and 20 ng/ml bFGF (all Thermo Fisher). All cells were maintained at 37 °C in a humidified atmosphere containing 5% CO2. During the course of this study, all cell lines were routinely confirmed to be mycoplasma negative (MycoAlert, Lonza, Basel, Switzerland).Cell pellets of at least 100,000 cells were washed with HBSS and frozen in liquid nitrogen. For homogenization, ceramic spheres (Lysing Matrix D, MP Biomedicals, Santa Ana, California, USA) and the FastPrep-24 homogenizer was used (MP Biomedicals, speed 4 m/s, tube holder MP:24*2 and time 20 s). Total RNA was isolated from 2D pellets using the NucleoSpin RNA Plus Kit (Macherey-Nagel, Düren, Germany) according to the manufacturer’s instructions. In total, 3 biological replicates of each cell line were processed respectively. RNA amount was determined using the Qubit RNA BR kit with the Qubit 4 (both ThermoFisher). Library preparation and RNA sequencing (transcriptome sequencing including lncRNA on Illumina PE150) were performed by Novogene (Cambridge, UK) Company Limited, Cambridge, UK. Samples with less than 100 ng or with non-qualifying RIN values were excluded from the sequencing. All prepared libraries successfully passed Novogene’s internal quality control checks and were sequenced. Following sequencing, quality control of the sequencing data was performed that confirmed all samples had high quality scores, indicating good technical performance of the sequencing. We used FastQC to perform quality checks of raw RNA data followed by adapter and low quality read filtering using the Cutadapt package (version 1.16.6) [reference]. The trimmed paired-end sequences were aligned with the human genome (hg38) and Gencode annotation (v35) using the STAR (version 2.7.5b) alignment tool. Unique reads from genomic alignment were processed and we used the featureCount tool for transcript abundance quantification. STAR read counts were used as input into edgeR. Genes with read counts greater than 10 in three or more samples were kept for subsequent analyses. After normalization analyses, counts per million (cpm) on a log2 scale were used for downstream exploratory analyses.

Project description:Crohn’s disease, which can affect any part of the gastrointestinal tract, is characterised by the formation of strictures and frequently requires surgery to manage symptoms, which increases morbidity and mortality. A better understanding of the strictured state is therefore needed to identify new targets for therapy. The aim of this study was to identify molecular signals of the strictured state. Sections from proximal, strictured and distal regions of resected colonoic tissue from Crohn’s disease patients undergoing surgery for stricturing disease, were collected in RNAlater. RNA was extracted using RNeasy columns (Qiagen) and quantified by Qubit (Life Technologies). 0.5ng RNA was used to prepare uniquely indexed cDNA QIAseq UPX 3’ Transcriptome libraries according to manufacturer’s instructions (Qiagen). Libraries were quantified and quality-controlled using the QIAseq Library Quant Assay Kit and tapestation analysis and sequenced on the Nextseq Illumina platform using the illumina sequencing primer and PhiX 15% to a depth of 1-3milion reads/sample. Read numbers were set as 101 bp (R1) x 51 bp (R2). Fastq files were obtained through BaseSpace and reads de-multiplexed, aligned to the human genome version GRCh38, quantified and normalised by the TPM method using the CLC Genomics Workbench (Qiagen). The following differential expression procedure was performed across the three sites. TPM normalised values were log-transformed with a pseudocount of 1 added. Transcripts with < 1 transformed count in any sample were excluded from further analysis, as were transcripts with low variance (defined as less than 10% unique counts across both conditions and greater than a 19:1 ratio of the most frequent count to the second most frequent across both conditions). Differential expression analysis between tissues was conducted with the limma package. Library size was estimated using reduced maximum likelihood estimator with 500 iterations. Initial fitting was performed using a robust M-estimation, and moderated test statistics computed by empirical Bayes. A FDR corrected p value <0.05 was considered and filtered for further downstream data analysis. Partial least squares discriminant analysis (PLS-DA) modelling was also performed on the genes, giving a Variable Importance in Projection (VIP) score was used to further rank the genes. VIP is a measure of a variable's importance in the PLS-DA model. To understand the biological significance and pathways, we also performed enrichment analysis using EnrichR with Gene ontology biological pathways, Wiki pathways and Kyoto Encyclopaedia of Genes and Genomes (KEGG). For those genes that showed strong statistical and biological relevance we assessed their combined ability to predict stricture vs non stricture using the Random Foreset Method of Area under the curve analysis.

Project description:The objective of this study was to identify pre-treatment colonic gene expression patterns in patients with inflammatory bowel disease (Ulcerative Colitis and colonic Crohn’s disease) that are predictive of a good versus poor response to treatment with the bioloic anti-TNFa. By identifying key pathways that are altered in responders versus non-responders we also aimed to propose novel targets for therapy. Pre-treatment colonic endoscopic biopsies were collected in RNAlater from 22 patients (14 CD and 8 UC) who were starting anti-TNFa therapy. RNA was extracted using RNeasy columns (Qiagen) and quantified by Qubit (Life Technologies). 0.5ng RNA was used to prepare uniquely indexed cDNA QIAseq UPX 3’ Transcriptome libraries according to manufacturer’s instructions (Qiagen). Libraries were quantified and quality-controlled using the QIAseq Library Quant Assay Kit and tapestation analysis and sequenced on the Miseq and Nextseq Illumina platforms using the illumina sequencing primer and PhiX 15% to a depth of 1-3milion reads/sample. Read numbers were set as 101 bp (R1) x 51 bp (R2). Fastq files were obtained through BaseSpace and reads de-multiplexed, aligned to human genome GRCh38, quantified and normalised by the TPM method using the CLC Genomics Workbench (Qiagen). The following differential expression procedure was performed for participants classified as responders, partial responders or non-responders according to their endoscopic presentation 12 weeks after therapy. For UC patients the Mayo score was used: Responders Mayo= 0, Partial responders 1<= Mayo <3 and Non Responders Mayo >=3. For CD patients % reduction in the SES-CD score was used: Responders >=50% of SES-CD, Partial responders 50%<SES-CD<75%, Non responders SES-CD > 75%. Normalised values were log-transformed with a pseudocount of 1 added. Transcripts with < 1 transformed count in any sample were excluded from further analysis, as were transcripts with low variance (defined as less than 10% unique counts across both conditions and greater than a 19:1 ratio of the most frequent count to the second most frequent across both conditions). Differential expression analysis between conditions was conducted with the limma package. Library size was estimated using reduced maximum likelihood estimator with 500 iterations. Initial fitting was performed using a robust M-estimation, and moderated test statistics computed by empirical Bayes. A FDR corrected p value <0.05 was considered and filtered for further downstream data analysis. Partial least squares discriminant analysis (PLS-DA) modelling was performed on these genes to calculate their variable Importance in Projection (VIP) score. To understand the biological significance and pathways represented in the DEGS, we also performed enrichment analysis using the DAVID Gene Functional Classification Tool (REF I,II). Finally, strongest indicators of response were predicted by Random Forest Area Under the Curve (AUC) analysis.

Dataset Information

RNA-seq of medulloblastoma spheroid models

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure